Molecular targeted therapy of malignant pleural mesothelioma

doi:10.3760/cma.j.issn.1673-422X.2014.01.017

Abstract

Abstract: Malignant pleural mesothelioma (MPM) is a rare form of cancer with latency period of 20 years, and it is now a period of high flows of MPM. It is often detected in late stages, and the efficacy of surgery, radiotherapy and second/thirdline chemotherapy still remains unknown except the classical firstline chemotherapy regimen contains pemetrexed and cisplatin. With the development of molecular targeted therapy, a new direction for individual therapy of MPM patient has been provided for the past few years.

Key words: Genes, Neoplasms, Malignant pleural mesothelioma, Molecular targeted therapy

Cheng Lei, Xu Yaping, Mao Weimin. Molecular targeted therapy of malignant pleural mesothelioma[J]. Journal of International Oncology, 2014, 41(1): 52-55.

References

［1］ Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study［J］. J Clin Oncol, 2007, 25(17):24062413. ［2］ Kai K, D′Costa S, Sills RC, et al. Inhibition of the insulinlike growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines［J］. Cancer Lett, 2009, 278(1):4955. ［3］ Mezzapelle R, Miglio U, Rena O, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma［J］. Br J Cancer, 2013, 108(8): 17431749. ［4］ Suzuki Y, Murakami H, Kawaguchi K, et al. Activation of the PI3KAKT pathway in human malignant mesothelioma cells［J］. Mol Med Rep, 2009, 2(2):181188. ［5］ Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients［J］. Eur J Cardiothorac Surg, 2008, 33(3):502506. ［6］ Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: a phase Ⅱ trial by the cancer and leukemia group B (CALGB 30107)［J］. Lung Cancer, 2012, 76(3):393396. ［7］ Garland LL, Chansky K, Wozniak AJ, et al. Phase Ⅱ study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509［J］. J Thorac Oncol, 2011, 6(11):19381945. ［8］ Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after firstline chemotherapy (NVALT 5): an openlabel, multicentre, randomised phase 3 study［J］. Lancet Oncol, 2013, 14(6):543551. ［9］ Pinto C, Ardizzoni A, Betta PG, et al. Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma［J］. Am J Clin Oncol, 2011, 34(1):99109. ［10］ Nowak AK, Millward MJ, Creaney J, et al. A phase Ⅱ study of intermittent sunitinib malate as secondline therapy in progressive malignant pleural mesothelioma［J］. J Thorac Oncol, 2012, 7(9):14491456. ［11］ Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma［J］. Cancer, 2008,113(4):808814. ［12］ Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, doubleblind, placebocontrolled, randomized phase Ⅱ trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma［J］. J Clin Oncol, 2012, 30(20): 25092515. ［13］ Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of singleagent imatinib mesylate in malignant pleural mesothelioma［J］. Cancer Chemother Pharmacol, 2007, 59(1):149150. ［14］ Dudek AZ, Pang H, Kratzke RA, et al. Phase Ⅱ study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report［J］. J Thorac Oncol, 2012, 7(4):755759. ［15］ Hartman ML, Esposito JM, Yeap BY, et al. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma［J］. J Thorac Cardiovasc Surg, 2010, 139(5):12331240. ［16］ Hoda MA, Mohamed A, Ghanim B, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy［J］. J Thorac Oncol, 2011, 6(5):852863. ［17］ Gregorc V, Zucali PA, Santoro A, et al. Phase Ⅱ study of asparagineglycineargininehuman tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma［J］. J Clin Oncol, 2010, 28(15):26042611. ［18］ Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials［J］. J Thorac Oncol, 2010, 5(2):275279. ［19］ Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproatedoxorubicin: promising therapy for progressing mesothelioma. A phase Ⅱ study［J］. Eur Respir J, 2011, 37(1):129135.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.